Eradication of therapy-resistant cancer cells in gastrointestinal organs (Review)

Nishikawa,Shimpei; Konno,Masamitsu; Hamabe ,Atsushi; Hasegawa,Shinichiro; Ogawa,Hisataka; Kano,Yoshihiro; Fukusumi,Takahito; Ohta,Katsuya; Noguchi,Yuko; Ozaki,Miyuki; Kudo,Toshihiro; Sakai,Daisuke; Haraguchi,Naotsugu; Satoh,Taroh; Doki,Yuichiro; Mori,Masaki; Ishii,Hideshi

doi:10.3892/mco.2012.13

Eradication of therapy-resistant cancer cells in gastrointestinal organs (Review)

Authors:
- Shimpei Nishikawa
- Masamitsu Konno
- Atsushi Hamabe
- Shinichiro Hasegawa
- Hisataka Ogawa
- Yoshihiro Kano
- Takahito Fukusumi
- Katsuya Ohta
- Yuko Noguchi
- Miyuki Ozaki
- Toshihiro Kudo
- Daisuke Sakai
- Naotsugu Haraguchi
- Taroh Satoh
- Yuichiro Doki
- Masaki Mori
- Hideshi Ishii
View Affiliations

Affiliations: Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, Osaka 565-0871, Japan, Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, Osaka 565-0871, Japan, Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, Osaka 565-0871, Japan
Published online on: August 20, 2012 https://doi.org/10.3892/mco.2012.13
Pages: 15-17

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Early stages of cancer are curable by surgical removal of the primary lesions, however, more advanced cases are often refractory to therapeutic approaches and are more commonly life-threatening, primarily due to cancer metastasis in gastrointestinal cancers. Such biological events are collectively characterized as tumor heterogeneity, the cause of which is the existence of cancer stem cells. To improve cancer survival, therapy-resistant cancer cells should be eradicated. To this end, recent rapid progress in medical science, such as innovative medical technologies including cancer reprogramming, RNA pharmacology and drug delivery systems, all of which effectively target cancer stem cells, has facilitated this objective.

View Figures

View References

1.	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000.
2.	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011.
3.	Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. 2006.
4.	Takahashi K, Tanabe K, Ohnuki M, et al: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861–872. 2007.
5.	Yamanaka S: Elite and stochastic models for induced pluripotent stem cell generation. Nature. 460:49–52. 2009.
6.	Miyoshi N, Ishii H, Nagai K, et al: Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA. 107:40–45. 2010.
7.	Nagai K-i, Ishii H, Miyoshi N, et al: Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. Biochem Biophysic Res Commun. 395:258–263. 2010.
8.	Zhao Y, Yin X, Qin H, et al: Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 3:475–479. 2008.
9.	Kawamura T, Suzuki J, Wang YV, et al: Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 460:1140–1144. 2009.
10.	Hong H, Takahashi K, Ichisaka T, et al: Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 460:1132–1135. 2009.
11.	Moon JH, Ishii H, Dewi DL, et al: Gain-of-function oncogenic mutations in TP53 enhance defined factor-mediated cellular reprogramming. Nat Preced. 2011. View Article : Google Scholar
12.	Yoshida Y, Takahashi K, Okita K, et al: Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 5:237–241. 2009.
13.	Hoshino H, Nagano H, Haraguchi N, et al: Hypoxia and TP53 deficiency for induced pluripotent stem cell-like properties in gastrointestinal cancer. Int J Oncol. 40:1423–1430. 2012.
14.	Anokye-Danso F, Trivedi CM, Juhr D, et al: Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 8:376–388. 2011.
15.	Miyoshi N, Ishii H, Nagano H, et al: Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 8:633–638. 2011.
16.	Lin SL, Chang DC, Ying SY, et al: MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 70:9473–9482. 2010.
17.	Lin SL, Chang DC, Chang-Lin S, et al: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 14:2115–2124. 2008.
18.	Fareh M, Turchi L, Virolle V, et al: The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 19:232–244. 2012.
19.	Dexter DL and Leith JT: Tumor heterogeneity and drug resistance. J Clin Oncol. 4:244–257. 1986.
20.	Adams JM and Strasser A: Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68:4018–4021. 2008.
21.	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001.
22.	Bonnet D and Dick JE: Human acute leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997.
23.	Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007.
24.	Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24:506–513. 2006.
25.	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007.
26.	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immuno-deficient mice. Nature. 445:106–110. 2007.
27.	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003.
28.	Piccirillo SG, Reynolds BA, Zanetti N, et al: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 444:761–765. 2006.
29.	Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006.
30.	Bixby S, Kruger GM, Mosher JT, et al: Cell-intrinsic differences between stem cells from different regions of the peripheral nervous system regulate the generation of neural diversity. Neuron. 35:643–656. 2002.
31.	Sagar J, Chaib B, Sales K, et al: Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 7:92007.
32.	Zhong J and Dai LC: Targeting liposomal nanomedicine to cancer therapy. Technol Cancer Res Treat. Mar 28–2012, (Epub ahead of print).
33.	Hurt EM, Chan K, Serrat MA, et al: Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 28:390–398. 2010.
34.	Yu CH, Law JB, Suryana M, et al: Early integrin binding to Arg-Gly-Asp peptide activates actin polymerization and contractile movement that stimulates outward translocation. Proc Natl Acad Sci USA. 108:20585–20590. 2011.